Dhanda D - Search Results

1

Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis.

van de Wetering G, Ignacio T, Dhanda D, Patel V, Zhang Y, Zhuo J. van de Wetering G, et al. Among authors: dhanda d. J Med Econ. 2022 Jan-Dec;25(1):421-427. doi: 10.1080/13696998.2022.2051912. J Med Econ. 2022. PMID: 35297738 Free article.

2

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.

Karampampa K, Zhang W, Venkatachalam M, Cotte FE, Dhanda D. Karampampa K, et al. Among authors: dhanda d. J Med Econ. 2023 Jan-Dec;26(1):243-253. doi: 10.1080/13696998.2023.2173466. J Med Econ. 2023. PMID: 36705644 Free article.

3

Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.

Thai S, Zhuo J, Zhong Y, Xia Q, Chen X, Bao Y, Dhanda D, Priya L, Wu JJ. Thai S, et al. Among authors: dhanda d. J Dermatolog Treat. 2023 Dec;34(1):2176708. doi: 10.1080/09546634.2023.2176708. J Dermatolog Treat. 2023. PMID: 36794863 Free article.

4

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.

Rivolo S, Di Fusco M, Polanco C, Kang A, Dhanda D, Savone M, Skandamis A, Kongnakorn T, Soto J. Rivolo S, et al. Among authors: dhanda d. PLoS One. 2021 Nov 12;16(11):e0259251. doi: 10.1371/journal.pone.0259251. eCollection 2021. PLoS One. 2021. PMID: 34767564 Free PMC article.

5

Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.

Ayers D, Cope S, Towle K, Mojebi A, Marshall T, Dhanda D. Ayers D, et al. Among authors: dhanda d. BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z. BMC Med Res Methodol. 2022. PMID: 36243687 Free PMC article.

6

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, Guo S, Yu P, Liao W, Campbell TB, Munshi NC. Delforge M, et al. Blood Adv. 2022 Feb 22;6(4):1309-1318. doi: 10.1182/bloodadvances.2021005913. Blood Adv. 2022. PMID: 34933328 Free PMC article.

7

Cost-effectiveness of atrial fibrillation screening in Canadian community practice.

Andrade JG, Shah A, Godin R, Lanitis T, Kongnakorn T, Brown L, Dhanda D, Dhamane A, Nault I. Andrade JG, et al. Among authors: dhanda d. Heart Rhythm O2. 2022 Nov 17;4(2):103-110. doi: 10.1016/j.hroo.2022.11.003. eCollection 2023 Feb. Heart Rhythm O2. 2022. PMID: 36873310 Free PMC article.

8

Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.

Dhanasiri S, Hollier-Hann G, Stothard C, Dhanda DS, Davies FE, Rodriguez-Otero P. Dhanasiri S, et al. Clin Ther. 2021 Nov;43(11):1983-1996.e3. doi: 10.1016/j.clinthera.2021.09.013. Epub 2021 Nov 2. Clin Ther. 2021. PMID: 34736769 Free article.

9

Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.

Shah N, Delforge M, San-Miguel J, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Miera M, Williams A, Murphy R, Devlen J, Hege K, Campbell TB, Munshi NC. Shah N, et al. Leuk Res. 2022 Sep;120:106921. doi: 10.1016/j.leukres.2022.106921. Epub 2022 Jul 21. Leuk Res. 2022. PMID: 35930999 Free article.

10

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.

Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Delforge M, et al. Among authors: dhanda ds. Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3. Leuk Res. 2023. PMID: 37087950 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters